Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

283 trials

NCT05831865
Recruiting
Frontline of ASCT in High-risk DLBCL
Not applicable · China · 1 site
Registry update: 6 May 2023
NCT05544019
Recruiting
Study of SGR-1505 in Mature B-Cell Neoplasms
Phase 1 · Spain, France, Italy, Moldova, Poland, Romania, Ukraine, United States · 37 sites
Registry update: 13 Feb 2026
NCT05800366
Recruiting
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Phase 2 · United States · 3 sites
Registry update: 5 Mar 2026
NCT05377307
Recruiting
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
Not applicable · Taiwan · 5 sites
Registry update: 9 Oct 2026
NCT05755087
Recruiting
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
Phase 1 · United States · 1 site
Registry update: 27 Feb 2026
NCT05735704
Recruiting
Early Detection and Screening of Hematological Malignancies - SANGUINE
Not applicable · Czechia, Greece, Israel, Lithuania · 4 sites
Registry update: 15 Oct 2026
NCT05256641
Recruiting
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Phase 1/2 · United States · 3 sites
Registry update: 10 Mar 2026
NCT05659628
Recruiting
CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL
Phase 1 · China · 2 sites
Registry update: 21 Dec 2022
NCT06005870
Recruiting
Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
Phase 2 · China · 1 site
Registry update: 18 May 2026
NCT05272384
Recruiting
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Phase 1 · United States · 9 sites
Registry update: 10 Sept 2026
NCT05514327
Recruiting
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
Not applicable · China · 1 site
Registry update: 24 Mar 2026
NCT05487170
Recruiting
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Phase 1/2 · China, United States · 5 sites
Registry update: 4 Mar 2025
NCT05255354
Recruiting
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
Not applicable · United States · 1 site
Registry update: 22 Aug 2024
NCT05518383
Recruiting
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
Phase 4 · Russia · 1 site
Registry update: 26 Aug 2022
NCT05366569
Recruiting
Bio-CAR-T BS Study
Not applicable · Italy · 1 site
Registry update: 30 Apr 2026
NCT05281809
Recruiting
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Phase 2 · United States · 1 site
Registry update: 13 Jan 2025
NCT05131022
Recruiting
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 · Switzerland, Spain, France, United Kingdom, Italy, Netherlands, Poland, United States · 62 sites
Registry update: 2 Jul 2026
NCT05257018
Recruiting
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
Phase 2 · China · 2 sites
Registry update: 2 Apr 2026
NCT06081478
Recruiting
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
Phase 2 · China · 1 site
Registry update: 13 Oct 2023
NCT05139017
Recruiting
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Phase 2/3 · Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, Denmark, France, United Kingdom, Greece, Guatemala, Hong Kong, Israel, Italy, Japan, South Korea, Mexico, New Zealand, Peru, Poland, Thailand, Ukraine, United States · 130 sites
Registry update: 3 Nov 2026
Conflicting statuses (updated in the registry within the last month)

Ordered by registry start date. Freshness and sponsorship never change the order.